Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent

MT newswire2026/09/28 21:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

05:17 PM EDT, 09/28/2026 (MT Newswires) -- Acadia Pharmaceuticals (ACAD) said late Monday the US Patent and Trademark Office issued a notice of allowance for a patent application covering weight-banded dosing of trofinetide for the treatment of Rett syndrome. The company said the patent, if issued, is expected to provide US protection for trofinetide through March 28, 2041, including six months of pediatric exclusivity, extending protection by nearly five years. Trofinetide is marketed in the US as "Daybue" and "Daybue Stix" for the treatment of Rett syndrome in adults and children age 2 and older. The drug is also covered by a method-of-use patent that expires in July 2036, the company said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

U.S. Treasury Secretary Janet Yellen defended the rise in U.S. Treasury yields, stating that this increase is a global phenomenon rather than unique to the United States, and does not warrant excessive concern. She partially attributed inflationary pressures to higher oil prices caused by the Iran conflict, and expects the energy shock to subside as hostilities ease. Yellen refuted the notion of an AI bubble, arguing that investments by major tech companies are grounded in solid business logic.

华尔街见闻•2026/10/04 03:06

Bitcoin Crash Warning Goes Viral as X Post Flags Benner Cycle

Coinpedia•2026/10/04 01:30